{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"langzeitverlauf-nach-absetzen-von-vemurafenib-braf-inhibitor-bei-der-erdheim-chester-krankheit-love-studie","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/de\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"Langzeitergebnisse nach Unterbrechung der Behandlung mit Vemurafenib bzw. BRAF-Hemmern bei der Erdheim-Chester-Krankheit (LOVE)"},"content":{"rendered":"<p><strong>Ziel der Studie:<\/strong> Bei ECD-Patienten, die mit Vemurafenib behandelt werden, scheint die Erkrankung stabil zu sein. In dieser Studie wird die M\u00f6glichkeit einer Behandlungsunterbrechung untersucht. K\u00fcrzlich wurden andere BRAF-Inhibitoren wie Dabrafenib zur Behandlung von BRAF-mutierten Histiozytosen vorgeschlagen. Auch die Unterbrechung der Behandlung mit anderen BRAF-Inhibitoren sollte prospektiv untersucht werden.<\/p>\n<p><strong>Projektleiter:<\/strong> Dr. med. Julien Haroche, Ph.D., H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, Frankreich<\/p>\n<p><strong>Kontaktdaten:<\/strong> Telefon: +33 1 42 17 80 37 E-Mail: julien.haroche@psl.aphp.fr<\/p>\n<p><strong>Gew\u00fcnschte Einbeziehung des Patienten:<\/strong> Patienten und behandelnde \u00c4rzte werden gebeten, sich f\u00fcr weitere Informationen an Prof. Julien Haroche zu wenden.<\/p>\n<p><strong>ClinicalTrials.gov-Kennung:<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}